Skip to main content
. 2013 Sep 16;122(19):3365–3375. doi: 10.1182/blood-2013-06-510586

Figure 2.

Figure 2

Expression of plasma miRNA signature for aGVHD diagnosis in a validation set. (A) Expression of miR-423, miR-199a-3p, miR-93*, miR-377, miR-155, and miR-30a in plasma of aGVHD (n = 57) and non-GVHD patients (n = 33) 6 weeks after HCT. (B) ROC analysis for individual miRNAs and combined miRNA signature including miR-423, miR-199a-3p, miR-93*, and miR-377 as described in the legend of Figure 1B. The equation of logistic regression in validation set was “Combined miRNA panel = 11.059 − 0.19 × miR-423 + 0.175 × miR-199a-3p-0.04 × miR-93* − 0.89 × miR-377.” (C) Comparison of sIL-2Rα protein levels in plasma between aGVHD and non-GVHD patients 6 weeks after HCT. (D) ROC curve of the 4-miRNA panel generated by analyzing all 168 samples from training and validation sets.